Compare Stocks → The Gold Grab of the Century (From Colonial Metals) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CPRXNASDAQ:GERNNASDAQ:SPPINASDAQ:TORCNASDAQ:VRNA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPRXCatalyst Pharmaceuticals$14.68-2.9%$15.50$11.09▼$17.76$1.73B0.891.48 million shs926,323 shsGERNGeron$3.56-0.6%$2.83$1.64▼$4.05$1.95B0.6211.11 million shs9.07 million shsSPPISpectrum Pharmaceuticals$1.03$1.01$0.32▼$1.57$211.41M2.151.93 million shsN/ATORCresTORbio$1.88-10.9%$12.16$0.86▼$10.50$68.35M2.431.15 million shs1.48 million shsVRNAVerona Pharma$15.31+0.5%$16.37$11.83▼$23.81$1.23B0.4404,120 shs499,479 shsThe 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPRXCatalyst Pharmaceuticals-2.91%-4.30%-6.79%+2.73%-8.36%GERNGeron-0.56%-4.56%+7.88%+64.81%+46.50%SPPISpectrum Pharmaceuticals0.00%0.00%0.00%0.00%+16.78%TORCresTORbio-10.71%-7.41%-16.29%-25.89%-68.22%VRNAVerona Pharma+0.46%-4.91%-5.14%-14.42%-31.47%World’s biggest multibillionaire investor is buying THIS by the ton [picture] (Ad)Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCPRXCatalyst Pharmaceuticals4.9911 of 5 stars4.51.00.03.93.13.34.4GERNGeron2.9974 of 5 stars3.51.00.01.32.01.70.6SPPISpectrum PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ATORCresTORbioN/AN/AN/AN/AN/AN/AN/AN/AVRNAVerona Pharma2.1492 of 5 stars3.52.00.00.02.71.70.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCPRXCatalyst Pharmaceuticals3.00Buy$26.4380.03% UpsideGERNGeron3.00Buy$5.3349.81% UpsideSPPISpectrum Pharmaceuticals2.00HoldN/AN/ATORCresTORbioN/AN/AN/AN/AVRNAVerona Pharma3.00Buy$33.60119.46% UpsideCurrent Analyst RatingsLatest TORC, SPPI, GERN, CPRX, and VRNA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/16/2024VRNAVerona PharmaPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$31.00 ➝ $36.004/11/2024GERNGeronNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.004/10/2024GERNGeronWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$6.003/27/2024CPRXCatalyst PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$29.003/22/2024CPRXCatalyst PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$34.003/15/2024GERNGeronWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$6.003/15/2024GERNGeronThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.00 ➝ $5.003/15/2024GERNGeronNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.00 ➝ $5.003/14/2024CPRXCatalyst PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$34.003/14/2024CPRXCatalyst PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$27.003/7/2024CPRXCatalyst PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$23.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCPRXCatalyst Pharmaceuticals$398.20M4.35$2.05 per share7.16$3.30 per share4.45GERNGeron$240K8,111.91N/AN/A$0.46 per share7.74SPPISpectrum Pharmaceuticals$10.11M20.91N/AN/A$0.15 per share6.87TORCresTORbioN/AN/AN/AN/A$2.24 per shareN/AVRNAVerona Pharma$460K2,689.90N/AN/A$3.10 per share4.94Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCPRXCatalyst Pharmaceuticals$71.41M$0.6124.076.730.8117.93%26.56%22.13%5/8/2024 (Confirmed)GERNGeron-$184.13M-$0.33N/AN/AN/A-77,691.14%-63.33%-44.71%5/9/2024 (Estimated)SPPISpectrum Pharmaceuticals-$75.40M-$0.36N/A14.71N/AN/A-218.44%-66.16%N/ATORCresTORbio-$82.74M-$2.41N/AN/AN/AN/A-78.12%-71.63%N/AVRNAVerona Pharma-$54.37M-$0.69N/AN/AN/AN/A-20.47%-17.72%5/9/2024 (Confirmed)Latest TORC, SPPI, GERN, CPRX, and VRNA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2024N/AVRNAVerona Pharma-$0.24N/A+$0.24N/AN/AN/A 5/8/2024N/ACPRXCatalyst Pharmaceuticals$0.31N/A-$0.31N/AN/AN/A 2/29/2024Q4 2023VRNAVerona Pharma-$0.23-$0.16+$0.07-$0.16N/AN/A2/28/2024Q4 2023CPRXCatalyst Pharmaceuticals$0.45$0.49+$0.04$0.67$105.78 million$110.57 million2/28/2024Q4 23GERNGeron-$0.10-$0.09+$0.01-$0.09$0.06 million$0.02 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCPRXCatalyst PharmaceuticalsN/AN/AN/AN/AN/AGERNGeronN/AN/AN/AN/AN/ASPPISpectrum PharmaceuticalsN/AN/AN/AN/AN/ATORCresTORbioN/AN/AN/AN/AN/AVRNAVerona PharmaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCPRXCatalyst PharmaceuticalsN/A2.882.68GERNGeron0.143.163.16SPPISpectrum PharmaceuticalsN/A2.712.38TORCresTORbioN/A20.6920.69VRNAVerona Pharma0.2033.3333.33OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCPRXCatalyst Pharmaceuticals79.22%GERNGeron73.71%SPPISpectrum Pharmaceuticals21.67%TORCresTORbio46.19%VRNAVerona Pharma85.88%Insider OwnershipCompanyInsider OwnershipCPRXCatalyst Pharmaceuticals12.10%GERNGeron3.10%SPPISpectrum Pharmaceuticals2.70%TORCresTORbio11.80%VRNAVerona Pharma4.80%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCPRXCatalyst Pharmaceuticals167118.01 million103.73 millionOptionableGERNGeron141546.87 million529.92 millionOptionableSPPISpectrum Pharmaceuticals86205.25 million199.70 millionOptionableTORCresTORbioN/A36.45 millionN/ANot OptionableVRNAVerona Pharma7980.82 million76.94 millionOptionableTORC, SPPI, GERN, CPRX, and VRNA HeadlinesSourceHeadlineJennison Associates LLC Acquires 142,819 Shares of Verona Pharma plc (NASDAQ:VRNA)marketbeat.com - April 25 at 7:26 AMVerona Pharma shares target raised on COPD launch outlookinvesting.com - April 25 at 3:40 AMVerona Pharma to Report First Quarter 2024 Financial Results and Provide Corporate Updateglobenewswire.com - April 25 at 2:00 AMVerona Pharma (NASDAQ:VRNA) Price Target Increased to $36.00 by Analysts at Piper Sandleramericanbankingnews.com - April 17 at 3:36 AMVerona Pharma (NASDAQ:VRNA) Trading 3.7% Higher After Analyst Upgradeamericanbankingnews.com - April 17 at 1:08 AMVerona Pharma (NASDAQ:VRNA) Stock Price Up 3.7% on Analyst Upgrademarketbeat.com - April 16 at 10:36 AMVerona Pharma (NASDAQ:VRNA) PT Raised to $36.00 at Piper Sandlermarketbeat.com - April 16 at 8:33 AMVerona Pharma (NASDAQ:VRNA) Shares Up 4.9%marketbeat.com - April 4 at 3:08 PMAmerican Century Companies Inc. Purchases Shares of 280,126 Verona Pharma plc (NASDAQ:VRNA)marketbeat.com - March 28 at 4:07 AMVRNA Apr 2024 17.500 callfinance.yahoo.com - March 16 at 8:32 AMVRNA Apr 2024 15.000 callfinance.yahoo.com - March 16 at 3:31 AMAndrew Fisher Joins Verona Pharma as General Counselglobenewswire.com - March 4 at 2:00 AMBuy Rating Affirmed: Verona Pharma’s Promising Future with Ensifentrine and Expanding R&D Pipelinemarkets.businessinsider.com - March 1 at 1:10 PMVerona Pharma plc (NASDAQ:VRNA) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 1 at 1:10 PM3 Healthcare Stocks That Have Outperformed Nvidia Since 2022fool.com - March 1 at 8:45 AMVerona Pharma plc 2023 Q4 - Results - Earnings Call Presentationseekingalpha.com - February 29 at 11:18 AMVerona Pharma plc: Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updatefinanznachrichten.de - February 29 at 10:48 AMVerona Pharma PLC Reports Fourth Quarter and Full Year 2023 Financial Resultsfinance.yahoo.com - February 29 at 10:48 AMVerona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updateglobenewswire.com - February 29 at 2:00 AMVerona Pharma earnings preview: what to expectmarkets.businessinsider.com - February 28 at 1:35 PMWhen Will Verona Pharma plc (NASDAQ:VRNA) Turn A Profit?finance.yahoo.com - February 25 at 12:52 PMVerona Pharma PLC ADRwsj.com - February 25 at 7:52 AMVRNA Mar 2024 15.000 putfinance.yahoo.com - February 17 at 7:46 PMVRNA Jun 2024 30.000 callfinance.yahoo.com - February 17 at 2:46 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCatalyst PharmaceuticalsNASDAQ:CPRXCatalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.GeronNASDAQ:GERNGeron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.Spectrum PharmaceuticalsNASDAQ:SPPISpectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and license agreement with Therapyx, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Boston, Massachusetts.resTORbioNASDAQ:TORCAdicet Bio, Inc. is a biotechnology company which engages in the design and development of off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.Verona PharmaNASDAQ:VRNAVerona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.